Abstract
The long-term effects of adjuvant polychemotherapy regimens in oestrogen-receptor-poor (ER-poor) breast cancer, and the extent to which these effects are modified by age or tamoxifen use, can be assessed by an updated meta-analysis of individual patient data from randomised trials. Collaborative meta-analyses of individual patient data for about 6000 women with ER-poor breast cancer in 46 trials of polychemotherapy versus not (non-taxane-based polychemotherapy, typically about six cycles; trial start dates 1975–96, median 1984) and about 14 000 women with ER-poor breast cancer in 50 trials of tamoxifen versus not (some trials in the presence and some in the absence of polychemotherapy; trial start dates 1972–93, median 1982).
Original language | English |
---|---|
Pages (from-to) | 29-40 |
Number of pages | 12 |
Journal | Lancet |
Volume | 371 |
Issue number | 9606 |
DOIs | |
Publication status | Published - 1 Jan 2008 |
Keywords
- breast cancer
- oestrogen receptor
- adjuvant therapy
- clinical trials
- chemotherapy